Experimental studies have demonstrated that L858R mutation in the EGF receptor (EGFR)
confers tumor sensitivity whereas T790M and L858R/T790M mutations cause resistance to …

Mutations in the kinase domain encoding region of EGFR gene causes drug resistance to
EGFR kinase inhibitors such as erlotinib and gefitinib. This problem can be addressed by a …

Activation of EGFR starts by ligand binding at the extracellular domain which results in homo
and heterodimerization, leading to phosphorylation, activation of downstream signaling …

Mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR),
including L858R/T790M double and L858R/T790M/C797S triple mutations, are major …

Emergence of resistant mutations in drug targets represents a serious problem in the
targeted chemotherapy. One challenging issue is to understand the atomic‐detailed effect of …

People's lives and health are gravely threatened by non-small-cell lung cancer (NSCLC).
Mutations in epidermal growth factor receptor (EGFR), a transmembrane receptor tyrosine …

Some individuals with non-small-cell lung cancer (NSCLC) benefit from therapies targeting
epidermal growth factor receptor (EGFR) and the characterization of a new mechanism of …

Background Epidermal growth factor receptor (EGFR) mutation-induced drug resistance has
caused great difficulties in the treatment of non-small-cell lung cancer (NSCLC). However …

Lung cancer is the leading cause of cancer death, and epidermal growth factor receptor
(EGFR) kinase domain mutations are a common cause of non-small-cell lung cancer …

The overexpression or mutation of the kinase domain of the epidermal growth factor receptor
(EGFR) is strongly associated with non-small-cell lung cancer (NSCLC). EGFR tyrosine …